Loading...
The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab
An elevated level of lipoprotein (a) [Lp(a)] is a risk factor for CVD. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is reported to reduce Lp(a) levels. The relationship of Lp(a) reduction with apo(a) size polymorphism, phenotype, and dominance pattern and LDL c...
Na minha lista:
| Udgivet i: | J Lipid Res |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
The American Society for Biochemistry and Molecular Biology
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5625124/ https://ncbi.nlm.nih.gov/pubmed/28798072 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.M078212 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|